H
Hiroaki Shimokawa
Researcher at Tohoku University
Publications - 976
Citations - 56856
Hiroaki Shimokawa is an academic researcher from Tohoku University. The author has contributed to research in topics: Heart failure & Endothelium. The author has an hindex of 111, co-authored 949 publications receiving 48822 citations. Previous affiliations of Hiroaki Shimokawa include University of Nebraska Medical Center & Nagoya University.
Papers
More filters
Journal Article
Abstract 281: Cyclophilin A is a Novel Biomarker for Oxidative Stress and Atherosclerotic Diseases
Kimio Satoh,Yoshihiro Fukumoto,Koichiro Sugimura,Yutaka Miura,Tatsuo Aoki,Kotaro Nochioka,Shunsuke Tatebe,Saori Yamamoto,Toru Shimizu,Yusuke Takagi,Ryuji Tsuburaya,Yoshitaka Ito,Yasuharu Matsumoto,Masaharu Nakayama,Morihiko Takeda,Jun Takahashi,Kenta Ito,Satoshi Yasuda,Hiroaki Shimokawa +18 more
TL;DR: Interestingly, plasma levels of CyPA increased according to the number of atherosclerotic risk factors that enhance oxidative stress, and was significantly reduced after medical treatment of those risk factors.
Journal Article
AN ANIMAL MODEL OF COLLATERAL DEVELOPMENT WITH REPEATED, BRIEF CORONARY OCCLUSION IN CONSCIOUS DOGS WITH NORMAL CORONARY ARTERIES : A NEW ASPECT OF COLLATERAL DEVELOPMENT : PROCEEDINGS OF THE 47th ANNUAL SCIENTIFIC MEETING OF THE JAPANESE CIRCULATION SOCIETY : Coronary Circulation
Journal Article
Abstract 74: Crucial Role of ROCK2 in Vascular Smooth Muscle Cells in Hypoxia-Induced Pulmonary Hypertension in Mice
TL;DR: VSMC- specific ROCK2-deficient (ROCK2+/-) and VSMC-specific ROCK2 -overexpressing (Rocked2-Tg) mice are developed and the extent of hypoxia-induced pulmonary hypertension was significantly reduced in ROCK2+/+ mice and was enhanced in ROCK 2-T g mice compared with the littermates.
Journal ArticleDOI
P793Usefulness and safety of fasudil, a selective Rho-kinase inhibitor, for PCI-related myocardial ischemia in interventional cardiology
Yoku Kikuchi,Jun Takahashi,Kenjiro Sato,Jun Sugisawa,Satoshi Tsuchiya,Akira Suda,Tomohiko Shindo,Shohei Ikeda,Kiyotaka Hao,Takashi Shiroto,Yotaro Matsumoto,Yasuhiko Sakata,Hiroaki Shimokawa +12 more
Journal Article
[The role of Rho-kinase pathway on PAH].
TL;DR: It is demonstrated that Rho-kinase is activated in animal models of PAH associated with enhanced pulmonary vasoconstricting and proliferating responses, impaired endothelial vasodilator functions, and pulmonary remodeling and that intravenous fasudil, a selective Rho -kinase inhibitor, exerts acute pulmonary vasodILator effects in patients with severe PAH.